Taylor Ben R, CFO of Recursion Pharmaceuticals ($RXRX), made two open market sales of company shares over the last year, totaling $131,000. His most recent sale occurred on February 18, 2026. These transactions rank 9,187th among 11,678 insiders by sale value, well below the average of $8.6 million across about 6.4 sales per insider. He reported no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 16, 2026 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Taylor Ben R | Chief Financial Officer | F | Class A Common Stock | 7075 | $3.42 | 1,188,274.0000 | 514,895,802 | 0.59% | 0.00% |
| March 17, 2026 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Taylor Ben R | Chief Financial Officer | S | Class A Common Stock | 7956 | $3.39 | 1,180,318.0000 | 514,895,802 | 0.67% | 0.00% |
| Feb. 17, 2026 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Taylor Ben R | Chief Financial Officer | F | Class A Common Stock | 11908 | $3.49 | 1,208,775.0000 | 514,895,802 | 0.98% | 0.00% |
| Feb. 18, 2026 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Taylor Ben R | Chief Financial Officer | S | Class A Common Stock | 13426 | $3.08 | 1,195,349.0000 | 514,895,802 | 1.11% | 0.00% |
| Feb. 6, 2026 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Taylor Ben R | Chief Financial Officer | A | Class A Common Stock | 446279 | $0.00 | 1,207,829.0000 | 514,895,802 | 58.60% | 0.09% |
| Feb. 6, 2026 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Taylor Ben R | Chief Financial Officer | F | Class A Common Stock | 11400 | $3.98 | 1,220,683.0000 | 514,895,802 | 0.93% | 0.00% |
| Feb. 6, 2026 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Taylor Ben R | Chief Financial Officer | A | Class A Common Stock | 24254 | $0.00 | 1,232,083.0000 | 514,895,802 | 2.01% | 0.00% |
| Dec. 29, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Taylor Ben R | Chief Financial Officer | S | Class A Common Stock | 21383 | $4.18 | 761,550.0000 | 514,895,802 | 2.73% | 0.00% |
| Dec. 15, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Taylor Ben R | Chief Financial Officer | F | Class A Common Stock | 7057 | $4.33 | 782,933.0000 | 514,895,802 | 0.89% | 0.00% |
| Nov. 25, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Taylor Ben R | Chief Financial Officer | F | Class A Common Stock | 2271 | $4.03 | 789,990.0000 | 514,895,802 | 0.29% | 0.00% |
| Nov. 17, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Taylor Ben R | Chief Financial Officer | F | Class A Common Stock | 11908 | $4.14 | 792,261.0000 | 514,895,802 | 1.48% | 0.00% |
| Sept. 15, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Taylor Ben R | Chief Financial Officer | F | Class A Common Stock | 7057 | $4.83 | 804,169.0000 | 395,072,094 | 0.87% | 0.00% |
| Aug. 15, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Taylor Ben R | Chief Financial Officer | F | Class A Common Stock | 11908 | $5.64 | 811,226.0000 | 395,072,094 | 1.45% | 0.00% |
| June 16, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Taylor Ben R | Chief Financial Officer | F | Class A Common Stock | 7057 | $4.92 | 823,134.0000 | 395,072,094 | 0.85% | 0.00% |
| May 15, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Taylor Ben R | Chief Financial Officer | F | Class A Common Stock | 11908 | $4.25 | 830,191.0000 | 395,072,094 | 1.41% | 0.00% |
| April 1, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Taylor Ben R | Chief Financial Officer | F | Class A Common Stock | 26571 | $5.10 | 842,099.0000 | 395,072,094 | 3.06% | 0.01% |
| March 17, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Taylor Ben R | Chief Financial Officer | F | Class A Common Stock | 7057 | $6.84 | 868,670.0000 | 395,072,094 | 0.81% | 0.00% |
| Feb. 18, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Taylor Ben R | Chief Financial Officer | F | Class A Common Stock | 10879 | $10.64 | 875,727.0000 | 395,072,094 | 1.23% | 0.00% |
| Feb. 3, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Taylor Ben R | Chief Financial Officer | A | Class A Common Stock | 13922 | $0.00 | 893,150.0000 | 395,072,094 | 1.58% | 0.00% |
| Feb. 3, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Taylor Ben R | Chief Financial Officer | A | Stock Option (Right to Buy) | 70037 | $0.00 | 1,274,462.0000 | 395,072,094 | 5.81% | 0.02% |
| Feb. 3, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Taylor Ben R | Chief Financial Officer | F | Class A Common Stock | 6544 | $7.25 | 886,606.0000 | 395,072,094 | 0.73% | 0.00% |
| Feb. 3, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Taylor Ben R | Chief Financial Officer | A | Class A Common Stock | 35018 | $0.00 | 879,228.0000 | 395,072,094 | 4.15% | 0.01% |
| Dec. 19, 2024 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Taylor Ben R | Chief Financial Officer | A | Stock Option (Right to Buy) | 740686 | $0.00 | 1,204,425.0000 | 0 | 159.72% | 0.00% |
| Dec. 19, 2024 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Taylor Ben R | Chief Financial Officer | A | Class A Common Stock | 370343 | $0.00 | 844,210.0000 | 0 | 78.15% | 0.00% |
| Dec. 17, 2024 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Taylor Ben R | Chief Financial Officer | F | Class A Common Stock | 7057 | $6.95 | 473,867.0000 | 0 | 1.47% | 0.00% |
| Dec. 16, 2024 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Taylor Ben R | Chief Financial Officer | F | Class A Common Stock | 15668 | $6.04 | 480,924.0000 | 0 | 3.16% | 0.00% |